⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 30 in last 7 days 🍎 Food: 2 in last 7 days 🧸 Products: 0 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 46 minutes ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 30 in last 7 days 🍎 Food: 2 in last 7 days 🧸 Products: 0 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 46 minutes ago
🛡️ EUSW
💊 Medicines 🍎 Food 🧸 Products 🔎 Search
📊 Data
🏷 Brands 🌍 Countries ℹ️ About ✉ Unsubscribe
🇬🇧
🇬🇧 English 🇳🇱 Nederlands 🇫🇷 Français 🇩🇪 Deutsch 🇪🇸 Español 🇮🇹 Italiano 🇵🇹 Português 🇵🇱 Polski 🇸🇪 Svenska 🇷🇴 Română 🇨🇿 Čeština 🇫🇮 Suomi 🇩🇰 Dansk
💊 Medicine AT August 13, 2026

Naloxon Amomed 0,4 mg/ml Injektionslösung 0,4 mg/ml (Injektionslösung)

📷 Wikipedia: Naloxone · Source
Naloxon Amomed 0,4 mg/ml Injektionslösung 0,4 mg/ml (Injektionslösung)
📷 Wikipedia: Naloxone · Source
Naloxone Amomed 0.4 mg/ml injection solution is subject to a parallel export ban.
⚠️
Shortage ongoing
NALOXON HYDROCHLORID is currently in short supply in AT.
📈 Timeline
29 days active so far
August 14, 2026 September 11, 2026

What is this? Naloxon Amomed is a medicine used to quickly reverse opioid overdoses. It comes as an injection.

What's happening? The medicine is currently unavailable in Austria. It is expected to be back in stock on September 15.

Does this affect me? If you or someone you know relies on this medicine, you may be affected until it returns.

What should I do? Ask your pharmacist or doctor for advice on alternative treatments while supplies are low.

🤖 This plain-language summary is automatically generated from the official agency notice using AI. It is for general information only — not medical advice. For decisions about your health, always consult a pharmacist or doctor and read the official source linked below.

🔬 Medical / technical details (for professionals)
Active substance(s)
NALOXON HYDROCHLORID
Agency-published detail

🚫 Parallel export ban active · ATC: V03AB15 · Reason: Erhöhter Mehrbedarf · Marketing authorisation holder: Amomed Pharma GmbH, Leopold Ungar Platz 2, 1190 Wien, Österreich · Affected packs: 10 Stück Schachtel, Ampulle [Nicht verfügbar, since 2026-08-13, resupply 2026-09-30]

First published
August 13, 2026
Last refreshed by us
18 hours ago
Severity (as classified)
High
Official source
https://medikamente.basg.gv.at/en/medicine-shortage

All information on this page comes from the official agency notice. We translate and summarise it; we don't add or edit facts.

❓ Frequently asked questions

▸ What is this medicine shortage alert about?
Naloxon Amomed 0,4 mg/ml Injektionslösung 0,4 mg/ml (Injektionslösung). Naloxone Amomed 0.4 mg/ml injection solution is subject to a parallel export ban.
▸ When was this alert issued?
This alert was issued on August 13, 2026 by BASG (Austria).
▸ Which countries are affected?
The alert applies to Austria.
▸ How serious is this alert?
Serious risk. A serious risk means the product or medicine can cause significant harm. Treat the alert as urgent.
▸ What should I do?
If you take this medicine, contact your pharmacist or prescribing doctor. They can advise on alternative products or substitutes. Do not stop taking prescription medicine without medical advice.
▸ Where can I find the official notice?
The full official notice is published on medikamente.basg.gv.at.

💬 Discussion

Share your experience or ask a question. Real names and email are optional but moderation friendly.

No comments yet — be the first.

We email a confirmation link. Your address stays private.

⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.